Posted On: 04/11/2014 8:51:15 PM
Post# of 89561
$ACT News
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Saumya Vaishampayan
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - blogs.marketwatch.com
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Staples awash in red; eBay up as Icahn posts new letter 4:09 p.m. March 6, 2014 - Victor Reklaitis
Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Acura Pharma Ends Agreement with Pfizer - Analyst Blog 5:35 p.m. Today - Zacks.com
Facebook, Arris, Grifols Initiate New Bases 5:35 p.m. Today - Investors Business Daily
3 Health Care Stocks Moving The Sector Upward 1:02 p.m. Today - TheStreet.com
Regulatory Update from Forest Labs - Analyst Blog 4:40 p.m. April 10, 2014 - Zacks.com
Actavis Becomes #157 Most Shorted S&P 500 Component, Replacing Vornado Realty Trust 3:19 p.m. April 10, 2014 - TheStreet.com
Buy Actavis - An Attractive Value And Growth Play That Is Also A Top Guru Fund Pick 12:27 a.m. April 10, 2014 - Seeking Alpha
Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape 8:37 a.m. April 9, 2014 - Zacks.com
Alexion, Biogen Among Leading Big-Cap Biotechs 7:02 a.m. April 9, 2014 - Investors Business Daily
Pacira and Patheon Collaborate - Analyst Blog 6:10 p.m. April 8, 2014 - Zacks.com
Additional Data on Pacira's Exparel - Analyst Blog 5:20 p.m. April 8, 2014 - Zacks.com
Should You Get Rid of Relypsa (RLYP) Now? - Tale of the Tape 8:44 a.m. April 7, 2014 - Zacks.com
Actavis PLC (ACT): Today's Featured Drugs Laggard 5:01 p.m. April 4, 2014 - TheStreet.com
Caesarstone, Other Leading Stocks Showing Supporting Action 4:49 p.m. April 4, 2014 - Investors Business Daily
Mylan Bid Gets Rejected, But Generic-Drugmaker Rises 4:28 p.m. April 4, 2014 - Investors Business Daily
3 Stocks Dragging The Drugs Industry Downward 1:02 p.m. April 4, 2014 - TheStreet.com
Mylan Rejected In Bid To Acquire Sweden's Meda 11:27 a.m. April 4, 2014 - Investors Business Daily
Mylan Eyes Swedish Drug Maker 10:12 p.m. April 3, 2014 - The Wall Street Journal Interactive Edition
Actavis Up Slightly on Silom Acquisition - Analyst Blog 3:56 p.m. April 3, 2014 - Zacks.com
Four Top World Stocks Offer Follow-On Buy Points 5:11 p.m. April 2, 2014 - Investors Business Daily
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog 6:00 p.m. April 1, 2014 - Zacks.com
Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin 8:00 a.m. Today - PR Newswire - PRF
Pharma Equities under Review -- Research on Mylan, Actavis, Hospira, and Medicines 12:30 p.m. April 10, 2014 - PR Newswire - PRF
Actavis Launches Asia Pacific Regional Headquarters in Singapore 8:00 p.m. April 2, 2014 - PR Newswire - PRF
Particle Sciences and Actavis Enter into Joint Development Agreement 11:00 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Acquires Silom Medical Company 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Completes Divestiture of Commercial Operations in Seven Western European Countries to Aurobindo Pharma Limited 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Lialda® Patent Suit 4:05 p.m. March 28, 2014 - PR Newswire - PRF
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic 8:00 a.m. March 26, 2014 - PR Newswire - PRF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% 5:00 p.m. March 25, 2014 - PR Newswire - PRF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% 5:00 p.m. March 25, 2014 - PR Newswire - PRF
Actavis to Host First Quarter 2014 Earnings Conference Call and Webcast 4:33 p.m. March 21, 2014 - PR Newswire - PRF
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis 11:11 a.m. March 21, 2014 - PR Newswire - PRF
Actavis Announces Daytrana® Patent Challenge Settlement 4:05 p.m. March 19, 2014 - PR Newswire - PRF
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus 8:00 a.m. March 13, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit 5:35 p.m. March 12, 2014 - PR Newswire - PRF
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis 6:50 a.m. March 7, 2014 - PR Newswire - PRF
Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
Intuitive Surgical slumps; Facebook extends rally 3:41 p.m. April 9, 2014 - Saumya Vaishampayan
Actavis acquires Silom Medical for $100 million 10:19 a.m. April 1, 2014 - MarketWatch.com
The 10 most overbought stocks in the S&P 500 index 12:19 p.m. March 25, 2014 - The Trading Deck
UK drug rejection, patent concerns take a bite out of Celgene shares 1:33 p.m. March 14, 2014 - blogs.marketwatch.com
Mylan to start selling generic Celebrex in May 7:22 a.m. March 13, 2014 - MarketWatch.com
Pfizer loses Celebrex patent ruling; shares halted but effect muted 3:21 p.m. March 12, 2014 - blogs.marketwatch.com
Staples awash in red; eBay up as Icahn posts new letter 4:09 p.m. March 6, 2014 - Victor Reklaitis
Icahn Enterprises reports profit up 144% in 2013 10:22 a.m. March 3, 2014 - MarketWatch
Citadel hedge fund’s recent moves 11:12 a.m. Feb. 25, 2014 - Insider Monkey
Stocks rally; S&P 500 ends right below record 4:45 p.m. Feb. 24, 2014 - Victor Reklaitis
U.S. stock market is starting to ride a tech M&A wave 5:31 a.m. Feb. 24, 2014 - Wallace Witkowski
Actavis continues hot streak with better-than-expected earnings 11:21 a.m. Feb. 20, 2014 - blogs.marketwatch.com
Actavis swings to loss on charges, write-downs 8:03 a.m. Feb. 20, 2014 - MarketWatch.com
Pharma megamergers bring higher profits, better returns, study says 1:59 p.m. Feb. 19, 2014 - blogs.marketwatch.com
Actavis, Forest shares continue their climb in aftermath of $25 billion deal 11:03 a.m. Feb. 19, 2014 - blogs.marketwatch.com
U.S. stocks edge up; Nasdaq gains for 8th day in a row 4:38 p.m. Feb. 18, 2014 - Anora Mahmudova
Forest Laboratories, Actavis surge on buyout deal 4:10 p.m. Feb. 18, 2014 - Ben Eisen
S&P 500, Nasdaq extend win streaks but Dow dips: stock market live blog recap 4:06 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Forest buyout may not spell the end of dealmaking for Actavis 3:00 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Pharma ETFs pop on the Actavis-Forest deal 2:07 p.m. Feb. 18, 2014 - blogs.marketwatch.com
Acura Pharma Ends Agreement with Pfizer - Analyst Blog 5:35 p.m. Today - Zacks.com
Facebook, Arris, Grifols Initiate New Bases 5:35 p.m. Today - Investors Business Daily
3 Health Care Stocks Moving The Sector Upward 1:02 p.m. Today - TheStreet.com
Regulatory Update from Forest Labs - Analyst Blog 4:40 p.m. April 10, 2014 - Zacks.com
Actavis Becomes #157 Most Shorted S&P 500 Component, Replacing Vornado Realty Trust 3:19 p.m. April 10, 2014 - TheStreet.com
Buy Actavis - An Attractive Value And Growth Play That Is Also A Top Guru Fund Pick 12:27 a.m. April 10, 2014 - Seeking Alpha
Mallinckrodt plc (MNK) in Focus: Stock Moves 5.3% Higher - Tale of the Tape 8:37 a.m. April 9, 2014 - Zacks.com
Alexion, Biogen Among Leading Big-Cap Biotechs 7:02 a.m. April 9, 2014 - Investors Business Daily
Pacira and Patheon Collaborate - Analyst Blog 6:10 p.m. April 8, 2014 - Zacks.com
Additional Data on Pacira's Exparel - Analyst Blog 5:20 p.m. April 8, 2014 - Zacks.com
Should You Get Rid of Relypsa (RLYP) Now? - Tale of the Tape 8:44 a.m. April 7, 2014 - Zacks.com
Actavis PLC (ACT): Today's Featured Drugs Laggard 5:01 p.m. April 4, 2014 - TheStreet.com
Caesarstone, Other Leading Stocks Showing Supporting Action 4:49 p.m. April 4, 2014 - Investors Business Daily
Mylan Bid Gets Rejected, But Generic-Drugmaker Rises 4:28 p.m. April 4, 2014 - Investors Business Daily
3 Stocks Dragging The Drugs Industry Downward 1:02 p.m. April 4, 2014 - TheStreet.com
Mylan Rejected In Bid To Acquire Sweden's Meda 11:27 a.m. April 4, 2014 - Investors Business Daily
Mylan Eyes Swedish Drug Maker 10:12 p.m. April 3, 2014 - The Wall Street Journal Interactive Edition
Actavis Up Slightly on Silom Acquisition - Analyst Blog 3:56 p.m. April 3, 2014 - Zacks.com
Four Top World Stocks Offer Follow-On Buy Points 5:11 p.m. April 2, 2014 - Investors Business Daily
Pacira Up as Exparel Site Gets FDA Nod - Analyst Blog 6:00 p.m. April 1, 2014 - Zacks.com
Recent Acquisitions, Trial Opinions, Upcoming Earnings, Inducement Grants, and Clinical Trial Results - Analyst Notes on Actavis, The Medicines Company, Hospira, Horizon Pharma, and Galectin 8:00 a.m. Today - PR Newswire - PRF
Pharma Equities under Review -- Research on Mylan, Actavis, Hospira, and Medicines 12:30 p.m. April 10, 2014 - PR Newswire - PRF
Actavis Launches Asia Pacific Regional Headquarters in Singapore 8:00 p.m. April 2, 2014 - PR Newswire - PRF
Particle Sciences and Actavis Enter into Joint Development Agreement 11:00 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Acquires Silom Medical Company 8:30 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Completes Divestiture of Commercial Operations in Seven Western European Countries to Aurobindo Pharma Limited 8:00 a.m. April 1, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Lialda® Patent Suit 4:05 p.m. March 28, 2014 - PR Newswire - PRF
Drug Approvals, Stock Price Movements, and New Tools for Standardization - Analyst Notes on Biogen Idec, Alexion, Actavis, Thermo Fisher Scientific, and Medtronic 8:00 a.m. March 26, 2014 - PR Newswire - PRF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% 5:00 p.m. March 25, 2014 - PR Newswire - PRF
Actavis and Valeant Announce FDA Approval for Metronidazole 1.3% 5:00 p.m. March 25, 2014 - PR Newswire - PRF
Actavis to Host First Quarter 2014 Earnings Conference Call and Webcast 4:33 p.m. March 21, 2014 - PR Newswire - PRF
Pharmaceutical Equities under Review -- Research on Zoetis, Mylan, AVANIR Pharma and Actavis 11:11 a.m. March 21, 2014 - PR Newswire - PRF
Actavis Announces Daytrana® Patent Challenge Settlement 4:05 p.m. March 19, 2014 - PR Newswire - PRF
New Drug Applications, Earnings Release Schedules, Drug Designations, New Services, and Clinical Trials - Analyst Notes on Actavis, Intercept, GW Pharmaceuticals, Galena, and Conatus 8:00 a.m. March 13, 2014 - PR Newswire - PRF
Actavis Confirms Favorable Ruling in Generic Celebrex® Patent Suit 5:35 p.m. March 12, 2014 - PR Newswire - PRF
Columbia Laboratories Repurchases 1.4 Million Shares of Common Stock from Actavis 6:50 a.m. March 7, 2014 - PR Newswire - PRF
Actavis to Present at Barclays Global Healthcare Conference 8:00 a.m. March 4, 2014 - PR Newswire - PRF
Actavis Confirms Generic Colcrys® Patent Challenge 4:05 p.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Confirms Generic Multaq® Patent Challenge 8:00 a.m. Feb. 28, 2014 - PR Newswire - PRF
Actavis Net Revenue Increases 59% to $2.779 Billion in Fourth Quarter 2013; Non-GAAP EPS Increases 99% to $3.17 7:00 a.m. Feb. 20, 2014 - PR Newswire - PRF
(0)
(0)
